Prostate cancer staging

Last updated

Prostate cancer staging is the process by which physicians categorize the risk of cancer having spread beyond the prostate, or equivalently, the probability of being cured with local therapies such as surgery or radiation. Once patients are placed in prognostic categories, this information can contribute to the selection of an optimal approach to treatment. Prostate cancer stage can be assessed by either clinical or pathological staging methods. [1] Clinical staging usually occurs before the first treatment and tumour presence is determined through imaging and rectal examination, while pathological staging is done after treatment once a biopsy is performed or the prostate is removed by looking at the cell types within the sample. [1]

Contents

There are two schemes commonly used to stage prostate cancer in the United States. The most common is promulgated by the American Joint Committee on Cancer (AJCC), and is known as the TNM system, which evaluates the size of the tumor, the extent of involved lymph nodes, and any metastasis (distant spread) and also takes into account cancer grade. [2] As with many other cancers, these are often grouped into four stages (I–IV). Another scheme that was used in the past was Whitmore-Jewett staging, although TNM staging is more common in modern practice. [3]

In the United Kingdom the 5-tiered Cambridge Prognostic Group (CPG) is used, replacing a previous system that divided prostate cancer into three risk groups. [4]

TNM staging

From the AJCC 7th edition [5] and UICC 7th edition. [6]

Stage I disease is cancer that is found incidentally in a small part of the sample when prostate tissue was removed for other reasons, such as benign prostatic hypertrophy, and the cells closely resemble normal cells and the gland feels normal to the examining finger. In Stage II more of the prostate is involved and a lump can be felt within the gland. In Stage III, the tumor has spread through the prostatic capsule and the lump can be felt on the surface of the gland. In Stage IV disease, the tumor has invaded nearby structures, or has spread to lymph nodes or other organs. The Gleason Grading System is based on cellular content and tissue architecture from biopsies, which provides an estimate of the destructive potential and ultimate prognosis of the disease.

Evaluation of the (primary) tumor ('T')

Clinical T stage (cT)

  • cTX: cannot evaluate the primary tumor
  • cT0: no evidence of tumor
  • cT1: tumor present, but not detectable clinically or with imaging
    • cT1a: tumor was incidentally found in 5% or less of prostate tissue resected (for other reasons)
    • cT1b: tumor was incidentally found in greater than 5% of prostate tissue resected
    • cT1c: tumor was found in a needle biopsy performed due to an elevated serum PSA
  • cT2: the tumor can be felt (palpated) on examination, but has not spread outside the prostate
    • cT2a: the tumor is in half or less than half of one of the prostate gland's two lobes
    • cT2b: the tumor is in more than half of one lobe, but not both
    • cT2c: the tumor is in both lobes but within the prostatic capsule
There may be adipose tissue within the prostate gland, but nevertheless, definite fat involvement by prostate cancer (as pictures) in a needle biopsy counts as extraprostatic or extracapsular spread. Histopathology of prostate adenocarcinoma involving adipose tissue.jpg
There may be adipose tissue within the prostate gland, but nevertheless, definite fat involvement by prostate cancer (as pictures) in a needle biopsy counts as extraprostatic or extracapsular spread.
In contrast, skeletal muscle is normally present within the prostate, so involvement thereof does not count as extraprostatic or extracapsular extension. Histopathology of prostate adenocarcinoma involving skeletal muscle.jpg
In contrast, skeletal muscle is normally present within the prostate, so involvement thereof does not count as extraprostatic or extracapsular extension.
  • cT3: the tumor has spread through the prostatic capsule (if it is only part-way through, it is still T2)
    • cT3a: the tumor has spread through the capsule on one or both sides
    • cT3b: the tumor has invaded one or both seminal vesicles
  • cT4: the tumor has invaded other nearby structures

It should be stressed that the designation "T2c" implies a tumor which is palpable in both lobes of the prostate. Tumors which are found to be bilateral on biopsy only but which are not palpable bilaterally should not be staged as T2c.

Pathological T stage (pT)

  • pT2: organ confined
    • pT2a: unilateral, one-half of one side or less
    • pT2b: unilateral, involving more than one-half of side, but not both sides
    • pT2c: bilateral disease
  • pT3: extraprostatic extension
    • pT3a: extraprostatic extension or microscopic invasion of bladder neck
    • pT3b: seminal vesicle invasion
  • pT4: invasion of rectum, levator muscles, and/or pelvic wall

Evaluation of the regional lymph nodes ('N')

Evaluation of distant metastasis ('M')

Evaluation of the histologic grade ('G')

Usually, the grade of the cancer (how different the tissue is from normal tissue) is evaluated separately from the stage. For prostate cancer, cell morphology is graded based on the Gleason grading system.[ citation needed ]

Of note, this system of describing tumors as "well-", "moderately-", and "poorly-" differentiated based on Gleason score of 2–4, 5–6, and 7–10, respectively, persists in SEER and other databases but is generally outdated. In recent years pathologists rarely assign a tumor a grade less than 3, particularly in biopsy tissue.[ citation needed ]

Grade Group classification ('GG')

A more contemporary reporting standard includes the Grade Groups. [9] [10] [11] For prostate cancer, grade group information and prostate-specific antigen levels are used in conjunction with TNM status to group cases into four overall stages. [10] [ citation needed ]

Overall staging

In the AJCC (2018) staging system, the tumor, lymph node, metastasis, gleason grade grouping and Prostate-specific antigen status can be combined into four stages of worsening severity. [12]

StageTumorNodesMetastasisGrade groupPSA5-year survival [13]
Stage IcT1aN0M0GG1<10100%
cT2a
pT2
Stage IIAcT110-20100%
cT2a or pT2
cT2b or cT2c<20
Stage IIBT1 or T2GG2
Stage IICGG3 or GG4
Stage IIIAT3GG1—495%
Stage IIIBT3 or T4Any PSA
Stage IIICAny TGG5
Stage IVAN1Any G30%
Stage IVBAny NM1

Whitmore-Jewett staging

Although it is no longer commonly used in practice, the Whitmore-Jewett system (also known as ABCD rating) is similar to the TNM system and has approximately equivalent stages. [3] Roman numerals are sometimes used instead of Latin letters for the overall stages (for example, Stage I for Stage A, Stage II for Stage B, and so on).[ citation needed ]

Cambridge Prognostic Group (CPG)

In the United Kingdom the NICE guidelines recommend using the Cambridge Prognostic Group (CPG) for categorising prostate cancer into 5 risk groups (CPG1 to CPG5). [4] This replaces an older system which used 3 risk groups (low, medium and high risk). [14] The CPG score is decided by looking at the Grade Group or Gleason score, the prostate specific antigen (PSA) level, and the clinical tumor stage. [15]

Risk groups

While TNM staging is important, systems based just on anatomic features are not well suited for deciding what treatment is best for a patient with prostate cancer, as there is still considerable heterogeneity of prognosis within the stage categories. A more refined prognosis can be established by consideration of prostate-specific antigen, and grade (i.e. Gleason score in the Gleason grading system). For example, it is common to classify patients into high, intermediate and low-risk groups on the basis of these three factors (TNM stage, PSA and Gleason score). There is no clear division between stage, which has historically described the anatomic extent of disease at diagnosis, and prognostic models that may include many features that contribute to clinical outcome.[ citation needed ]

If treated, patients with low-risk disease are usually treated with active surveillance, prostatectomy, or radiotherapy alone. Patients with intermediate-risk disease are candidates for prostatectomy or radiotherapy and a short duration (less than 6 months) of hormonal ablation (medical castration using a gonadotropin-releasing hormone analog). Although the role of surgery in these patients remains uncertain, those with high-risk disease are usually treated with radiotherapy and a long duration of hormonal ablation. Many high-risk patients are not cured by this treatment, and the search for better treatments in this group is a particularly pressing concern in prostate cancer research.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Prostate cancer</span> Male reproductive organ cancer

Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder. Abnormal growth of prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels. Those with high levels of PSA in their blood are at increased risk for developing prostate cancer. Diagnosis requires a biopsy of the prostate. If cancer is present, the pathologist assigns a Gleason score, and a higher score represents a more dangerous tumor. Medical imaging is performed to look for cancer that has spread outside the prostate. Based on the Gleason score, PSA levels, and imaging results, a cancer case is assigned a stage 1 to 4. A higher stage signifies a more advanced, more dangerous disease.

<span class="mw-page-title-main">Sarcoma</span> Cancer originating in connective tissue

A sarcoma is a malignant tumor, a type of cancer that arises from cells of mesenchymal origin. Connective tissue is a broad term that includes bone, cartilage, muscle, fat, vascular, or other structural tissues, and sarcomas can arise in any of these types of tissues. As a result, there are many subtypes of sarcoma, which are classified based on the specific tissue and type of cell from which the tumor originates.

<span class="mw-page-title-main">Carcinoma</span> Malignancy that develops from epithelial cells

Carcinoma is a malignancy that develops from epithelial cells. Specifically, a carcinoma is a cancer that begins in a tissue that lines the inner or outer surfaces of the body, and that arises from cells originating in the endodermal, mesodermal or ectodermal germ layer during embryogenesis.

<span class="mw-page-title-main">Kidney cancer</span> Medical condition

Kidney cancer, also known as renal cancer, is a group of cancers that starts in the kidney. Symptoms may include blood in the urine, a lump in the abdomen, or back pain. Fever, weight loss, and tiredness may also occur. Complications can include spread to the lungs or brain.

The TNM Classification of Malignant Tumors (TNM) is a globally recognised standard for classifying the anatomical extent of the spread of malignant tumours (cancer). It has gained wide international acceptance for many solid tumor cancers, but is not applicable to leukaemia or tumors of the central nervous system. Most common tumors have their own TNM classification. The TNM staging system is sometimes referred to as the AJCC/UICC staging system or the UICC/AJCC staging system. Several revisions have been published, the latest being the eighth edition in 2017.

In medicine, Breslow's depth was used as a prognostic factor in melanoma of the skin. It is a description of how deeply tumor cells have invaded. Currently, the standard Breslow's depth has been replaced by the AJCC depth, in the AJCC staging system of melanoma. Originally, Breslow's depth was divided into 5 stages.

Cancer staging is the process of determining the extent to which a cancer has grown and spread. A number from I to IV is assigned, with I being an isolated cancer and IV being a cancer that has metastasized and spread from its origin. The stage generally takes into account the size of a tumor, whether it has invaded adjacent organs, how many regional (nearby) lymph nodes it has spread to, and whether it has appeared in more distant locations (metastasized).

This is a list of terms related to oncology. The original source for this list was the US National Cancer Institute's public domain Dictionary of Cancer Terms.

Ann Arbor staging is the staging system for lymphomas, both in Hodgkin's lymphoma and non-Hodgkin lymphoma. It was initially developed for Hodgkin's, but has some use in NHL. It has roughly the same function as TNM staging in solid tumors.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

<span class="mw-page-title-main">Sentinel lymph node</span> First lymph node to receive drainage from a primary tumor

The sentinel lymph node is the hypothetical first lymph node or group of nodes draining a cancer. In case of established cancerous dissemination it is postulated that the sentinel lymph nodes are the target organs primarily reached by metastasizing cancer cells from the tumor.

<span class="mw-page-title-main">Gleason grading system</span> Score given to a prostate cancer based on its microscopic appearance

The Gleason grading system is used to help evaluate the prognosis of men with prostate cancer using samples from a prostate biopsy. Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy. A Gleason score is given to prostate cancer based upon its microscopic appearance.

<span class="mw-page-title-main">Papillary thyroid cancer</span> Medical condition

Papillary thyroid cancer is the most common type of thyroid cancer, representing 75 percent to 85 percent of all thyroid cancer cases. It occurs more frequently in women and presents in the 20–55 year age group. It is also the predominant cancer type in children with thyroid cancer, and in patients with thyroid cancer who have had previous radiation to the head and neck. It is often well-differentiated, slow-growing, and localized, although it can metastasize.

<span class="mw-page-title-main">Cervical lymph nodes</span> Lymph nodes found in the neck

Cervical lymph nodes are lymph nodes found in the neck. Of the 800 lymph nodes in the human body, 300 are in the neck. Cervical lymph nodes are subject to a number of different pathological conditions including tumours, infection and inflammation.

<span class="mw-page-title-main">Medullary breast carcinoma</span> Rare type of breast cancer

Medullary breast carcinoma is a rare type of breast cancer that is characterized as a relatively circumscribed tumor with pushing, rather than infiltrating, margins. It is histologically characterized as poorly differentiated cells with abundant cytoplasm and pleomorphic high grade vesicular nuclei. It involves lymphocytic infiltration in and around the tumor and can appear to be brown in appearance with necrosis and hemorrhage. Prognosis is measured through staging but can often be treated successfully and has a better prognosis than other infiltrating breast carcinomas.

Lung cancer staging is the assessment of the extent to which a lung cancer has spread from its original source. As with most cancers, staging is an important determinant of treatment and prognosis. In general, more advanced stages of cancer are less amenable to treatment and have a worse prognosis.

Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated.

<span class="mw-page-title-main">Cervical cancer staging</span> Medical condition

Cervical cancer staging is the assessment of cervical cancer to determine the extent of the spread of cancer beyond the cervix. This is important for determining how serious the cancer is and to create the best treatment plan.

Colon cancer staging is an estimate of the amount of penetration of a particular cancer. It is performed for diagnostic and research purposes, and to determine the best method of treatment. The systems for staging colorectal cancers depend on the extent of local invasion, the degree of lymph node involvement and whether there is distant metastasis.

Prognostic markers are biomarkers used to measure the progress of a disease in the patient sample. Prognostic markers are useful to stratify the patients into groups, guiding towards precise medicine discovery. The widely used prognostic markers in cancers include stage, size, grade, node and metastasis. In addition to these common markers, there are prognostic markers specific to different cancer types. For example estrogen level, progesterone and HER2 are markers specific to breast cancer patients. There is evidence showing that genes behaving as tumor suppressors or carcinogens could act as prognostic markers due to altered gene expression or mutation. Besides genetic biomarkers, there are also biomarkers that are detected in plasma or body fluid which can be metabolic or protein biomarkers.

References

  1. 1 2 Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM (January 2012). "Staging of prostate cancer". Histopathology. 60 (1): 87–117. doi:10.1111/j.1365-2559.2011.04025.x. PMID   22212080. S2CID   29345205.
  2. "AJCC 7th edition; Prostate cancer staging" (PDF). cancerstaging.org.
  3. 1 2 Dunnick, R (2012-10-16). Textbook of uroradiology. Sandler, C., Newhouse, J. ([5th edition] ed.). Philadelphia. p. 322. ISBN   9781451171617. OCLC   820121202.{{cite book}}: CS1 maint: location missing publisher (link)
  4. 1 2 "Prostate cancer: diagnosis and management. NICE guideline [NG131]". National Institute for Health and Care Excellence (NICE). 9 May 2019. Retrieved 2022-10-03.
  5. Edge SB, ed. (2010). AJCC cancer staging manual (7th ed.). New York: Springer. pp. 457–468. ISBN   9780387884400.
  6. "TNM | UICC". Union for International Cancer Control. Retrieved 11 November 2017.
  7. Image by Mikael Häggström, MD. Reference for implication: Grignon DJ (2018). "Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens". Mod Pathol. 31 (S1): S96-109. doi:10.1038/modpathol.2017.167. PMID   29297497.
  8. Image by Mikael Häggström, MD. Reference for implication: Ye H, Walsh PC, Epstein JI (2010). "Skeletal muscle involvement by limited Gleason score 6 adenocarcinoma of the prostate on needle biopsy is not associated with adverse findings at radical prostatectomy". J Urol. 184 (6): 2308–12. doi:10.1016/j.juro.2010.08.006. PMID   20952012.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. "Grade groups". American Cancer Society.
  10. 1 2 Pierorazio PM, Walsh PC, Partin AW, Epstein JI (May 2013). "Prognostic Gleason grade grouping: data based on the modified Gleason scoring system". BJU International. 111 (5): 753–760. doi:10.1111/j.1464-410X.2012.11611.x. PMC   3978145 . PMID   23464824.
  11. Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (July 2016). "The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours" (PDF). European Urology. 70 (1): 106–119. doi:10.1016/j.eururo.2016.02.028. PMID   26996659. S2CID   3756845.
  12. "How prostate cancer is staged". American Cancer Society.
  13. "Survival: Prostate cancer". Cancer Research UK.
  14. "2021 exceptional surveillance of prostate cancer: diagnosis and management (NICE guideline NG131)". National Institute for Health and Care Excellence (NICE). 9 May 2019. Retrieved 2022-10-03.
  15. "Prostate cancer risk groups and the Cambridge Prognostic Group (CPG)". Cancer Research UK. Retrieved 2022-10-03.